Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOTIS-5: loncastuximab tesirine + rituximab versus R-GemOx in relapsed or refractory DLBCL
NL-OMON53841Phase 3Recruiting
- Sponsor
- ADC Therapeutics
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of loncastuximab tesirine and rituximab in diffuse large B-cell lymphoma (DLBCL) and large-cell lymphoma (2 arms), sponsored by ADC Therapeutics. Primary endpoint: Progression-free survival. Started May 2023; status: recruiting.
02
Drugs
loncastuximab tesirinerituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)large-cell lymphoma
Beyond the preview
Go deeper on NL-OMON53841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53841.